clinical trial · NCT06680232
Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B
Precision BioSciences, Inc.·phase1·recruiting·n = 45
HEPATITIS B CHRONICPBGENE-HBV
brief summary
This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.
started
Nov 14, 2024
primary completion
Dec 1, 2025
completion
Dec 1, 2026
last updated
Sep 26, 2025
detailed description
Refer to key Inclusion and Exclusion criteria.
official title
A Phase 1, Open-Label, First-in-Human, Dose Escalation (Part 1) and Expansion (Part 2) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of PBGENE-HBV in Participants With Chronic Hepatitis B (ELIMINATE-B)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol